Busulfan–fludarabine- or treosulfan–fludarabine-based myeloablative conditioning for children with thalassemia major

• Published in: Annals of hematology 2022-03, Vol.101 (3), p.655-665
• Main Authors: Lüftinger, Roswitha, Zubarovskaya, Natalia, Galimard, Jacques-Emmanuel, Cseh, Annamaria, Salzer, Elisabeth, Locatelli, Franco, Algeri, Mattia, Yesilipek, Akif, de la Fuente, Josu, Isgrò, Antonella, Alseraihy, Amal, Angelucci, Emanuele, Smiers, Frans J., La La Nasa, Giorgia, Zecca, Marco, Fisgin, Tunc, Unal, Emel, Kleinschmidt, Katharina, Peters, Christina, Lankester, Arjan, Corbacioglu, Selim
• Format: Article
• Language: English
• Subjects: Adolescent; Antineoplastic Agents - therapeutic use; beta-Thalassemia - therapy; Blood diseases; Busulfan - analogs & derivatives; Busulfan - therapeutic use; Child; Child, Preschool; Clinical trials; Confidence intervals; Female; Graft versus host disease; Hematology; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents - therapeutic use; Infant; Iron; Male; Medicine; Medicine & Public Health; Mortality; Myeloablative Agonists - therapeutic use; Neutrophils; Oncology; Original Article; Palliative care; Pediatrics; Quality of life; Retrospective Studies; Stem cell transplantation; Toxicity; Transplantation Conditioning; Vidarabine - analogs & derivatives; Vidarabine - therapeutic use
• ISSN: 0939-5555; 1432-0584
• DOI: 10.1007/s00277-021-04732-4

Significant advances in supportive care for patients with transfusion-dependent thalassemia major (TDT) have improved patients’ life expectancy. However, transfusion-associated iron overload remains a significant barrier to long-term survival with good quality of life. Today, allogeneic hematopoietic stem cell transplantation (HSCT) is the current curative standard of care. Alongside selection of the best available donor, an optimized conditioning regimen is crucial to maximize outcomes for patients with TDT undergoing HSCT. The aim of this retrospective analysis was to investigate the role of busulfan–fludarabine-based and treosulfan–fludarabine-based conditioning in TDT patients undergoing HSCT. We included 772 patients registered in the European Society for Blood and Marrow Transplantation (EBMT) database who underwent first HSCT between 2010 and 2018. Four hundred ten patients received busulfan–fludarabine-based conditioning (median age 8.6 years) and 362 patients received treosulfan–fludarabine-based conditioning (median age 5.7 years). Patient outcomes were retrospectively compared by conditioning regimen. Two-year overall survival was 92.7% (95% confidence interval: 89.3–95.1%) after busulfan–fludarabine-based conditioning and 94.7% (95% confidence interval: 91.7–96.6%) after treosulfan–fludarabine-based conditioning. There was a very low incidence of second HSCT overall. The main causes of death were infections, graft-versus-host disease, and rejection. In conclusion, use of busulfan or treosulfan as the backbone of myeloablative conditioning for patients with TDT undergoing HSCT resulted in comparably high cure rates. Long-term follow-up studies are warranted to address the important issues of organ toxicities and gonadal function.